These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 19956079)
1. Unintended impacts of a Medicaid prior authorization policy on access to medications for bipolar illness. Lu CY; Soumerai SB; Ross-Degnan D; Zhang F; Adams AS Med Care; 2010 Jan; 48(1):4-9. PubMed ID: 19956079 [TBL] [Abstract][Full Text] [Related]
2. Effects of prior authorization on medication discontinuation among Medicaid beneficiaries with bipolar disorder. Zhang Y; Adams AS; Ross-Degnan D; Zhang F; Soumerai SB Psychiatr Serv; 2009 Apr; 60(4):520-7. PubMed ID: 19339328 [TBL] [Abstract][Full Text] [Related]
4. Impact of two Medicaid prior-authorization policies on antihypertensive use and costs among Michigan and Indiana residents dually enrolled in Medicaid and Medicare: results of a longitudinal, population-based study. Law MR; Lu CY; Soumerai SB; Graves AJ; LeCates RF; Zhang F; Ross-Degnan D; Adams AS Clin Ther; 2010 Apr; 32(4):729-41; discussion 716. PubMed ID: 20435243 [TBL] [Abstract][Full Text] [Related]
5. Association between prior authorization for medications and health service use by Medicaid patients with bipolar disorder. Lu CY; Adams AS; Ross-Degnan D; Zhang F; Zhang Y; Salzman C; Soumerai SB Psychiatr Serv; 2011 Feb; 62(2):186-93. PubMed ID: 21285097 [TBL] [Abstract][Full Text] [Related]
6. Impact of prior authorization on the use and costs of lipid-lowering medications among Michigan and Indiana dual enrollees in Medicaid and Medicare: results of a longitudinal, population-based study. Lu CY; Law MR; Soumerai SB; Graves AJ; LeCates RF; Zhang F; Ross-Degnan D; Adams AS Clin Ther; 2011 Jan; 33(1):135-44. PubMed ID: 21397779 [TBL] [Abstract][Full Text] [Related]
7. Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change. Soumerai SB; Zhang F; Ross-Degnan D; Ball DE; LeCates RF; Law MR; Hughes TE; Chapman D; Adams AS Health Aff (Millwood); 2008; 27(3):w185-95. PubMed ID: 18381404 [TBL] [Abstract][Full Text] [Related]
8. Spillover effects of state medicaid antipsychotic prior authorization policies in US commercially insured youth. Spence O; Reeves G; dosReis S Pharmacoepidemiol Drug Saf; 2020 Sep; 29(9):1064-1071. PubMed ID: 32558177 [TBL] [Abstract][Full Text] [Related]
9. "Impact of drug-reimbursement policies on prescribing: A case-study of a newly marketed long-acting injectable antipsychotic among relapsed schizophrenia patients". Jackson JW; Fulchino L; Rogers J; Mogun H; Polinski J; Henderson DC; Schneeweiss S; Fischer MA Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):95-104. PubMed ID: 29168261 [TBL] [Abstract][Full Text] [Related]
10. Cost and utilization of behavioral health medications associated with rescission of an exemption for prior authorization for severe and persistent mental illness in the Vermont Medicaid Program. Simeone JC; Marcoux RM; Quilliam BJ J Manag Care Pharm; 2010 Jun; 16(5):317-28. PubMed ID: 20518584 [TBL] [Abstract][Full Text] [Related]
12. Assessment of changes in utilization of health-care services after implementation of a prior authorization policy for atypical antipsychotic agents. Walthour A; Seymour L; Tackett R; Perri M Ann Pharmacother; 2010 May; 44(5):809-18. PubMed ID: 20388858 [TBL] [Abstract][Full Text] [Related]
13. Changes in drug coverage generosity and untreated serious mental illness: transitioning from Medicaid to Medicare Part D. Madden JM; Adams AS; LeCates RF; Ross-Degnan D; Zhang F; Huskamp HA; Gilden DM; Soumerai SB JAMA Psychiatry; 2015 Feb; 72(2):179-88. PubMed ID: 25588123 [TBL] [Abstract][Full Text] [Related]
14. Effect of prior authorization of second-generation antipsychotic agents on pharmacy utilization and reimbursements. Law MR; Ross-Degnan D; Soumerai SB Psychiatr Serv; 2008 May; 59(5):540-6. PubMed ID: 18451014 [TBL] [Abstract][Full Text] [Related]
15. Healthcare costs of atypical antipsychotic use for patients with bipolar disorder in a Medicaid programme. Qiu Y; Fu AZ; Liu GG; Christensen DB Appl Health Econ Health Policy; 2010; 8(3):167-77. PubMed ID: 20408601 [TBL] [Abstract][Full Text] [Related]
16. Formulary restrictions on atypical antipsychotics: impact on costs for patients with schizophrenia and bipolar disorder in Medicaid. Seabury SA; Goldman DP; Kalsekar I; Sheehan JJ; Laubmeier K; Lakdawalla DN Am J Manag Care; 2014 Feb; 20(2):e52-60. PubMed ID: 24738555 [TBL] [Abstract][Full Text] [Related]
17. Comparison of second-generation antipsychotic treatment on psychiatric hospitalization in Medicaid beneficiaries with bipolar disorder. Jing Y; Johnston SS; Fowler R; Bates JA; Forbes RA; Hebden T J Med Econ; 2011; 14(6):777-86. PubMed ID: 21954966 [TBL] [Abstract][Full Text] [Related]
18. Treatment costs related to bipolar disorder and comorbid conditions among Medicaid patients with bipolar disorder. Guo JJ; Keck PE; Li H; Patel NC Psychiatr Serv; 2007 Aug; 58(8):1073-8. PubMed ID: 17664518 [TBL] [Abstract][Full Text] [Related]
19. Effects of a limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. Soumerai SB; McLaughlin TJ; Ross-Degnan D; Casteris CS; Bollini P N Engl J Med; 1994 Sep; 331(10):650-5. PubMed ID: 8052275 [TBL] [Abstract][Full Text] [Related]